18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: Long-term results

Rigacci, Luigi; Castagnoli, Antonio; Dini, Carlotta Sorini; Carpaneto, Andrea; Matteini, Maria; Alterini, Renato; Carrai, Valentina; Nassi, Luca; Bernardi, Franco; Pieroni, Cesco; Bosi, Alberto

doi:10.3892/or.14.5.1209

Cited by 19 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The scores for internal and external validity are presented in Tables 8 (CT), 9 (FDG-PET), and 10 (FDG-PET/CT fusion). For the CT studies, the FDG-PET studies, and the FDG-PET/CT fusion studies, the total scores for combined internal and external validity, expressed as a fraction of the maximum score, ranged from 50% to 58% 38 2005…”

Section: Methodological Quality Assessmentmentioning

confidence: 99%

“…Results of the 3 studies investigating CT [38][39][40] are displayed in Table 11. Only one study (separately) investigated patients with HD, with sensitivity and specificity of 87.5% and 85.6% (regionbased) for initial staging, and sensitivity and specificity of 85.7% and 75.6% (region-based) for restaging, respectively.…”

Section: Diagnostic Performancementioning

confidence: 99%

“…39 The other 2 studies were performed in a mixture of patients with HD and NHL, with sensitivities of 25% and 100% (patient-based) and specificities of 41.7% and 58.8% (patient-based) for restaging, respectively. 38,40 FDG-PET. Results of the 17 studies investigating FDG-PET [38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54] are displayed in Table 12.…”

Section: Diagnostic Performancementioning

confidence: 99%

See 2 more Smart Citations

Imaging in staging of malignant lymphoma: a systematic review

Kwee

Nievelstein

2008

Blood

230

145

View full text Add to dashboard Cite

IntroductionThe malignant lymphomas, Hodgkin disease (HD) and nonHodgkin lymphoma (NHL), comprise approximately 5% to 6% of all malignancies and are the fifth most frequently occurring type of cancer in the United States. In 2007, an estimated 9260 new cases of HD and 81 850 new cases of NHL will be diagnosed in the United States. 1 Once the diagnosis HD or NHL has been established by biopsy of a particular site, determination of disease extent (staging) is important for appropriate treatment planning and determining prognosis. In addition, knowing the sites of involvement at time of diagnosis makes it possible to accurately restage at the end of therapy and document a complete remission. 2,3 Staging of HD and NHL is based on the Ann Arbor classification with the addition of a definition of bulky disease often referred to as the Cotswold modification (Table 1). This staging system encompasses the number of sites of disease involved, the type of involvement (nodal or extranodal), and the distribution of disease. 4 Computed tomography (CT) is currently the most commonly used means for staging patients with malignant lymphoma. 2,3 However, CT lacks functional information, which impedes identification of disease in normal-sized organs. 18 F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) may be an alternative to CT. 5,6 Other promising alternatives to CT are FDG-PET/CT fusion 7,8 and whole-body magnetic resonance imaging (WB-MRI). 9,10 The purpose of this study is to provide an up-to-date overview of the diagnostic performance of CT, FDG-PET, FDG-PET/CT fusion, and WB-MRI in staging of malignant lymphoma.In the first part of this article, technical aspects and procedures of each imaging modality are summarized. Subsequently, we describe our literature search strategy, study selection methods, and study analysis. Next, literature search results and results of analyzed articles are demonstrated. Finally, results are discussed, and advantages, drawbacks, and limitations of each imaging technique are outlined. Technical aspects and procedures CTBefore the CT era, patients with a diagnosis of malignant lymphoma were subjected to a battery of radiologic studies that included chest radiography, intravenous pyelography, lymphangiography, skeletal surveys, and isotope scans. On top of this, most patients with HD underwent staging laparotomy with its attendant risks. 11 The introduction of CT in the early 1970s was a tremendous breakthrough in noninvasive imaging, and its potential for staging malignant lymphoma was soon recognized and investigated. 12 Since then, CT has gradually become the imaging modality of choice for staging malignant lymphoma. CT technology has continuously been developed and refined; major milestones include the introduction of spiral CT in the early 1990s and the advent of multidetector-row CT in 1998. The concept of multidetector-row CT deserves special attention; multidetector-row CT scanners have multiple (X) data acquisition systems connected to multidetector arrays to provide a multi...

show abstract

Section: Methodological Quality Assessmentmentioning

confidence: 99%

Section: Diagnostic Performancementioning

confidence: 99%

Section: Diagnostic Performancementioning

confidence: 99%

See 1 more Smart Citation

Imaging in staging of malignant lymphoma: a systematic review

Kwee

Nievelstein

2008

Blood

230

145

View full text Add to dashboard Cite

show abstract

“…При этом в зоне исходных поражений нередко выявляют остаточные образования, которые могут быть как активными опу-холями, так и носить посттерапевтический характер. Возможности дифференциации этих состояний при КТ весьма ограниченны [3,4]. Поэтому для оценки эффек-тивности лечения лимфом рекомендована позитрон-ная эмиссионная томография (ПЭТ) с 18-фтордезок-сиглюкозой (ФДГ), а при морфологических вариантах лимфом, вариабельно накапливающих ФДГ, -КТ [5].…”

Section: Introductionunclassified

Comparison of diagnostic effectiveness of X-ray computed tomography, magnetic resonance imaging and diffusion-weighted magnetic resonance imaging in the differentiation of residual tumors and posttherapeutic masses in patients with lymphoma after treatment

Хоружик¹,

Zhavrid²,

Сачивко³

2016

Onkogematologiâ

View full text Add to dashboard Cite

Сравнение диагностической эффективности рентгеновской компьютерной томографии, магнитно-резонансной томографии и диффузионно-взвешенной магнитно-резонансной томографии при дифференциации остаточных опухолей и образований посттерапевтического характера у пациентов с лимфомами после завершения лечения

show abstract

“…In 28 patients following treatment for HD, CT had a sensitivity of 25% and a specificity of 42% whereas PET had a sensitivity and specificity of 100% and 83% respectively. 16 …”

Section: Lymphomamentioning

confidence: 99%

PET in Halifax

Chung¹,

Zoost²,

Burrell³

2011

DMJ

View full text Add to dashboard Cite

With the recent installation of a PET-CT scanner in Halifax, local clinicians may now take advantage of PET's various applications in the field of oncology, where it has become a standard of care. PET also plays a role in the areas of cardiology and neurology although it has not yet been approved for these uses in Nova Scotia. This article describes the basic principles of PET and radiopharmaceuticals as well as PET's increasing role in the management of patients in the areas of oncology, neurology and cardiology. PET shows significant promise in these areas and clinicians should be familiar with its many applications.

show abstract

18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: Long-term results

Cited by 19 publications

References 0 publications

Imaging in staging of malignant lymphoma: a systematic review

Imaging in staging of malignant lymphoma: a systematic review

Comparison of diagnostic effectiveness of X-ray computed tomography, magnetic resonance imaging and diffusion-weighted magnetic resonance imaging in the differentiation of residual tumors and posttherapeutic masses in patients with lymphoma after treatment

PET in Halifax

Contact Info

Product

Resources

About